Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI 
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push 
Add as a preferred source on Google
Hanmi Pharmaceutical will get US$10 million from Merck Sharp & Dohme (MSD) as initial contract payment in an $860 million exclusive licensing deal for the development, manufacture, and commercialization of its liver treatment candidate material efinopegdutide.
Under the deal, Hamni will be getting royalty payments from MSD with the development of the efinopegdutide.
However, the overall payment MSD will give Hanmi is contingent on regulatory permission and the drug's success in the market.
Efinopegdutide is for treating nonalcoholic steatohepatitis (NASH), a condition where the liver suffers inflammation and damage due to excess fat in the organ.
The South Korean pharmaceutical firm claimed findings from the latest phase 2 studies have provided compelling clinical evidence that the material can be used on people with NASH.
Efinopegdutide was originally developed for insulin secretion and obesity control, in cooperation with Janssen Pharmaceutica.
A 2015 deal to develop and market the drug through due to shortfalls related to blood sugar level control.
